GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

That’s more than double the $290.5 million generated last year by Krystal Biotech’s marketed therapy Vyjuvek® (beremagene geperpavec-svdt)—the third highest sales of any gene therapy in ...

Krystal’s redosable topical approach — priced at around $200,000–$400,000 per year — earned around $290 million in annual sales in 2024. Abeona first submitted its gene therapy for FDA ...

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease ... which said it stands to make £334 million ($443 million) from the sale, a threefold return on its original £113 ...

The COVID-19 pandemic has bit into sales at Novartis ... Results also showed a strong launch for its rare diseases gene therapy, Zolgensma, which is now approved for the muscle wasting disease ...

Pacira BioSciences, Inc. announced that it will present findings from a Phase 1 study of its gene therapy candidate ... 0 have been purchases and 2 have been sales. Here’s a breakdown of ...

The data highlight the therapeutic potential of coAAV-CSF-01 (S01coAAV2) to transform central nervous system (CNS) gene therapy delivery ... separation between our sales teams and authors to ...

MeiraGTx Holdings plc announced that the FDA has granted its investigational gene therapy AAV-GAD the Regenerative ... 0 have been purchases and 5 have been sales. Here’s a breakdown of recent ...

Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT ... separation between our sales teams and authors to remove ...